Skip to content

Author

Erik A. Imel

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Metaphyseal changes on whole-body magnetic resonance imaging following bisphosphonate therapy in children with chronic nonbacterial osteomyelitis: distinguishing treatment effect from disease flare.

BACKGROUND Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory disease that often affects the metaphyses. Bisphosphonates, a second-line therapy, can cause bone marrow changes that may mimic active disease. OBJECTIVE To characterize metaphyseal long-bone marrow changes on whole-body MRI (WB-MRI) following...

Boaz Karmazyn, Hilary B. Kleppel, S. Chilukuri et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults with X-Linked Hypophosphatemia (XLH): A 3-Year Follow-Up of the XLH Disease Monitoring Program.

X-linked hypophosphatemia (XLH) is a progressive disease in which excess FGF23 causes renal phosphate wasting, leading to hypophosphatemia. Consequences in adults include osteomalacia, fractures, pseudofractures, joint dysfunction, pain, and impaired mobility. Treatments for XLH are the anti-FGF23 antibody burosumab an...

Steven W. Ing, S. Bowden, Kathryn M. Dahir et al. · 0 citations
Review Open access Aug 2026

Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review

Increasing awareness of TIO in children may prevent delays in diagnosis, reduce the need for radiation-conferring tests, and lower morbidity due to effective management due to effective management.

S. Minisola, S. Jan de Beur, Thomas O. Carpenter et al. · 0 citations
Open access Jul 2026

HR-pQCT measures of bone in autosomal dominant osteopetrosis highly correlate with fractures and inversely correlate with bone resorption markers

Overall, the data reveal the profound, yet variable, phenotype in ADO and indicate that HR-pQCT measures correlate with disease severity and represent potential surrogate endpoints for future therapeutic trials.

Stuart J. Warden, Erik A. Imel, Zi-Yue Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.